Coca-Cola Consolidated, Inc.
COKE
$200.67
+4.18%
Coca-Cola Consolidated, Inc. is the largest independent Coca-Cola bottler in the United States, manufacturing, marketing, and distributing a broad portfolio of nonalcoholic beverages — sparkling sodas (led by Coca-Cola), bottled water, energy drinks, ready-to-drink tea and coffee, juices, and sports drinks — across its Nonalcoholic Beverages and All Other operating segments. Unlike The Coca-Cola Company, which owns the concentrate and brand IP, COKE operates as a capital-intensive franchise bottler and distributor, giving it a distinct, lower-margin but highly cash-generative position within the Coca-Cola system. The current investor narrative centers on the company's aggressive capital-return program and balance-sheet transformation: management has been retiring debt and buying back stock at scale, which has sharply reduced share count and amplified per-share earnings growth even as revenue growth moderates. At the same time, the stock's 55% one-year gain has made valuation a central debate, with the market weighing whether the bottler's margin expansion and buyback-driven EPS compounding can justify a multiple that has re-rated well above its historical band.…
COKE
Coca-Cola Consolidated, Inc.
$200.67
Investment Opinion: Should I buy COKE Today?
Based on the synthesized data, COKE warrants a Hold rating. The core thesis is that the company's aggressive buyback program and stable cash flows provide support, but margin compression and a lack of analyst consensus limit near-term upside. With only one analyst covering the stock and no price target, the typical anchor for a recommendation is missing, but the trailing PE of 19.78x and PEG of 1.87x suggest the stock is fairly valued to slightly rich.
Supporting evidence includes revenue growth of 16.88% year-over-year in Q1 2026, a stable gross margin around 39.37%, and trailing free cash flow of $662.1 million. The current ratio of 1.26 indicates solid liquidity, and the dividend yield of 0.77% with a low payout ratio of 15.2% leaves room for continued distributions. However, the net margin has fallen to 6.04% from 10.10% in Q2 2025, and interest expense has surged to $32.1 million, which could pressure earnings if not managed.
The biggest risks are further margin erosion, a slowdown in buybacks, and the stock's thin liquidity. The rating would upgrade to Buy if net margin stabilizes above 8% and interest expenses decline, or if the stock pulls back to the $163 support level with improving fundamentals. It would downgrade to Sell if revenue growth turns negative or if free cash flow falls below $500 million. Relative to its historical PE range of 8-76x, the current 19.78x is mid-range, but on a PS basis of 1.56x, it is near the low end, suggesting the stock is not overvalued on sales. Overall, COKE appears fairly valued, with a slight tilt toward undervaluation on cash flow metrics.
Sign up to view all
COKE 12-Month Price Forecast
COKE presents a mixed picture: strong cash generation and buyback-driven EPS growth are offset by margin pressure and a lack of analyst validation. The stock's low beta and defensive characteristics are appealing, but the 6-month relative underperformance and negative equity raise concerns. The base case is most likely, with the stock trading in a range as the market awaits clearer signs of margin stabilization. An upgrade to bullish would require evidence of net margin recovery and increased analyst coverage; a downgrade to bearish would occur if margins deteriorate further or buybacks slow.
Wall Street consensus
Insufficient analyst coverage available: only 1 analyst covers COKE, with a recommendation of "none" and no estimated EPS figures (average, low, and high all reported as 0). The sole revenue estimate is $7.228 billion, which annualizes the current run-rate and implies modest growth from the trailing four-quarter total. With a single analyst and no consensus rating or price target, there is no meaningful consensus target price to calculate implied upside or downside from the current $192.61. The absence of a formal recommendation means the consensus sentiment cannot be characterized as bullish, neutral, or bearish — the stock simply lacks the sell-side infrastructure to generate a directional signal. The target range cannot be presented because no low or high targets exist in the data. The institutional ratings history is stale, with the most recent action being Citigroup maintaining a "Neutral" rating in May 2016 — over a decade ago — and no upgrades or downgrades since. This near-total absence of analyst coverage is characteristic of a mid-cap, family-controlled, low-float bottler that institutional investors often overlook; it implies less efficient price discovery, higher idiosyncratic volatility around earnings, and a stock that trades more on flows and fundamentals than on sell-side narrative. For investors, the lack of coverage is a double-edged sword: it reduces the risk of downgrade-driven selloffs but also means the stock can remain mispriced for extended periods, and the wide information gap rewards independent fundamental research.
Drowning in data?
Find the real signal!
Bulls vs Bears: COKE Investment Factors
The bull case rests on COKE's aggressive capital return program, which has slashed share count by over 35% in a year, and its stable, cash-generative bottling business with a low beta of 0.547. Revenue growth of 16.88% year-over-year and $662.1 million in trailing free cash flow provide fundamental support. However, the bear case highlights deteriorating net margins due to rising interest expense, negative equity from buybacks, and a PEG ratio of 1.87x that suggests the stock is not undervalued. The most critical tension is whether the buyback-driven EPS growth can continue to offset margin pressure and justify the current valuation, especially given the stock's 11.20% six-month decline and thin analyst coverage. Currently, the bear evidence appears slightly stronger due to the margin compression and lack of analyst validation, but the bull case could regain dominance if interest expenses stabilize and buybacks persist.
Bullish
- Aggressive Buyback Shrinks Share Count: Shares outstanding fell from 87.18 million in Q1 2025 to 56.52 million in Q1 2026, a 35.2% reduction, driven by $2.46 billion of repurchases in Q4 2025 alone. This mechanical reduction amplifies EPS growth even with flat net income, and the company retains capacity to continue given $662.1 million in trailing free cash flow.
- Revenue Growth Accelerating: Q1 2026 revenue rose 16.88% year-over-year to $1.847 billion, up from $1.580 billion in Q1 2025. While quarterly revenue has been stable around $1.85-$1.90 billion, the YoY acceleration reflects pricing power and favorable mix, supporting the top-line narrative.
- Strong Relative Performance and Low Beta: COKE has gained 55.14% over the past year versus SPY's 16.22%, delivering 38.92 percentage points of relative strength, all while maintaining a beta of only 0.547. This combination of high relative return and low volatility is rare and suggests efficient risk-adjusted performance.
- Robust Free Cash Flow and Healthy Current Ratio: Trailing free cash flow is $662.1 million, and the current ratio stands at 1.26, indicating ample liquidity. Q1 2026 operating cash flow of $205.3 million comfortably covered capex of $63.1 million, leaving $142.2 million in free cash flow for debt reduction, buybacks, and dividends.
Bearish
- Net Margin Compression from Rising Interest: Net margin fell from 10.10% in Q2 2025 to 6.04% in Q1 2026, largely due to interest expense surging to $32.1 million from $5.9 million over the same period. This sharp increase in financing costs is eating into profitability and could worsen if debt levels remain elevated.
- Negative Shareholders' Equity and High Leverage: Debt-to-equity is -4.06 and ROE is -77.13%, both artifacts of negative book equity resulting from massive buybacks. While not an immediate solvency threat, negative equity reduces financial flexibility and could limit access to capital if cash flows deteriorate.
- Valuation Gap and PEG Ratio Suggest Fair to Rich Pricing: The trailing PE of 19.78x is mid-range historically, but the PEG ratio of 1.87x indicates the stock is not cheap relative to its growth rate. The forward PE of 4.95x appears distorted by depressed trailing EPS, and the market may be overestimating the earnings recovery.
- Weak 6-Month Momentum and Relative Underperformance: Despite a strong 1-year gain, COKE has declined 11.20% over the past six months, underperforming SPY by 26.60 percentage points. This suggests the uptrend has stalled and the stock is in a corrective phase, with resistance at the 52-week high of $219.65.
COKE Technical Analysis
COKE is in a sustained, powerful uptrend, with a 1-year price change of +55.14% versus SPY's +16.22%, delivering relative strength of +38.92 percentage points over the trailing year. The current price of $192.61 sits at roughly 76.5% of the 52-week range (low $110.60, high $219.65), meaning the stock is in the upper quartile of its annual band but has not yet reclaimed its high — it is consolidating below resistance rather than pressing into new highs. This positioning suggests a stock with strong underlying momentum that is digesting a sharp prior advance; it is neither an overextended breakout nor a value opportunity near the lows, but rather a mid-range pullback within a larger uptrend. The 6-month change of -11.20% is the key caveat: despite the strong 1-year gain, the stock has lost ground over the past two quarters, indicating the uptrend has stalled and entered a corrective phase. Short-term momentum has turned constructive again, with a 1-month gain of +2.03% and a 3-month gain of +2.51%, both modestly positive but far below the 1-year pace — momentum is decelerating from its prior trajectory. Notably, COKE's 1-month relative strength of +3.09% versus SPY's -1.06% shows the stock outperforming a weak market, a bullish divergence, while the 6-month relative strength of -26.60% versus SPY's +15.40% reveals the stock badly lagged during the spring selloff. The 1-month and 3-month gains conflicting with the negative 6-month trend signal a potential mean-reversion recovery attempt within a broader consolidation, not yet a confirmed trend reversal. Key technical support sits at the 52-week low of $110.60, with intermediate support around the $163-$170 area where the stock bottomed in May 2026; resistance is the 52-week high of $219.65, and a breakout above that level would signal resumption of the primary uptrend. A breakdown below $163 would invalidate the recovery thesis and open the door to a retest of the lows. With a beta of just 0.547, COKE is roughly 45% less volatile than the market, meaning its 55% one-year gain was achieved with below-market volatility — an unusually favorable risk-adjusted profile that supports larger position sizing for volatility-aware investors, though the 5.82 short ratio and 701,817 daily volume indicate a relatively thin, less liquid trading profile that can amplify gap moves.
Beta
0.55
0.55x market volatility
Max Drawdown
-24.7%
Largest decline past year
52-Week Range
$111-$220
Price range past year
Annual Return
+64.5%
Cumulative gain past year
| Period | COKE Return | S&P 500 |
|---|---|---|
| 1m | +6.1% | -2.0% |
| 3m | +7.8% | +1.4% |
| 6m | -5.7% | +15.0% |
| 1y | +64.5% | +15.7% |
| ytd | +33.9% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COKE Fundamental Analysis
Revenue is growing at a healthy clip, with the most recent quarter (Q1 2026, ended 2026-04-03) delivering $1.847 billion, up 16.88% year-over-year from $1.580 billion in Q1 2025. The multi-quarter trend shows sequential stability: Q2 2025 revenue was $1.856 billion, Q3 2025 was $1.888 billion, Q4 2025 was $1.904 billion, and Q1 2026 was $1.847 billion — essentially flat at roughly $1.85-$1.90 billion per quarter, indicating the YoY growth is driven by pricing/mix and comparison against a weak prior-year base rather than volume acceleration. Segment data confirms concentration: the Nonalcoholic Beverage segment generated $1.834 billion of the $1.847 billion total (99.3%), with the Other segment contributing just $89.5 million, so the investment case is entirely levered to the core bottling business. The growth trend implies a mature, steady-state business where revenue expansion is modest and the real earnings story comes from margin and share-count dynamics rather than top-line acceleration. Profitability is solid and improving: Q1 2026 net income was $111.6 million on a 6.04% net margin, with gross margin of 39.37% and operating margin of 12.86%. Comparing recent quarters, gross margin has been remarkably stable in the 38.2%-40.0% range (Q2 2025: 40.02%, Q3 2025: 39.64%, Q4 2025: 38.21%, Q1 2026: 39.37%), while net margin has compressed from the 10.10% peak in Q2 2025 to 6.04% in Q1 2026 — a notable deterioration driven by higher interest expense ($32.1 million in Q1 2026 versus $5.9 million in Q2 2025) and other income/expense swings. The company remains comfortably profitable, but the margin trajectory warrants monitoring as interest costs have risen sharply. Balance-sheet and cash-flow metrics present a mixed picture: trailing free cash flow is $662.1 million, Q1 2026 operating cash flow was $205.3 million against capex of $63.1 million (FCF of $142.2 million), and the current ratio is a healthy 1.26. However, the reported debt-to-equity ratio of -4.06 and ROE of -77.13% are artifacts of negative shareholders' equity — the company has repurchased so much stock ($2.46 billion in Q4 2025 alone) that book equity has gone negative, which also explains the negative P/B of -15.26. This is not a solvency crisis but a capital-structure choice: the company generates enough operating cash to fund capex and dividends internally, and it has been using excess cash plus debt capacity to retire shares aggressively. The risk is that negative equity and heavy buybacks leave less cushion if cash flows deteriorate, and the 0.77% dividend yield with a 15.2% payout ratio leaves room for continued distributions.
Quarterly Revenue
$1.8B
2026-04
Revenue YoY Growth
+16.9%
YoY Comparison
Gross Margin
39.4%
Latest Quarter
Free Cash Flow
$662108000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COKE Overvalued?
Because COKE is profitable — Q1 2026 net income of $111.6 million and trailing EPS of $0.0505 (reflecting the diluted share count and one-time items) — the PE ratio is the appropriate primary metric, though the trailing PE of 19.78x and forward PE of 4.95x present a striking gap. The forward PE of 4.95x implies the market expects earnings to roughly quadruple from trailing levels, which is almost certainly an artifact of depressed trailing EPS rather than a genuine four-fold earnings explosion; the quarterly EPS figures ($1.97 in Q1 2026, $1.84 in Q4 2025, $1.86 in Q3 2025) annualize to roughly $7.50, suggesting the trailing PE is distorted by the share-count and diluted-EPS mechanics. The gap between trailing and forward PE signals the market is pricing in a sharp normalization of earnings, but the magnitude of the gap warrants skepticism about the forward estimate's reliability. On a peer-comparison basis, COKE's PS ratio of 1.56x and EV/Sales of 0.369x are low in absolute terms, but the EV/EBITDA of 13.55x is more informative for a capital-intensive bottler and sits at a moderate level. The PEG ratio of 1.87x suggests the stock is not cheap relative to its growth rate, and the P/CF of 12.05x is reasonable for a cash-generative defensive business. Compared to the broader Consumer Defensive sector, where beverage peers often trade at 20-25x earnings, COKE's trailing PE of 19.78x is roughly in line to slightly below sector averages, but the negative P/B of -15.26x makes book-value comparisons meaningless. The premium/discount assessment is complicated by the negative equity: on cash-flow and sales metrics COKE looks inexpensive, but on earnings and PEG it looks fairly valued to slightly rich. Historical context is revealing: COKE's PE ratio has ranged from 8.12x (Q3 2022) to 75.88x (Q4 2021) over the past five years, with recent readings of 24.71x (Q1 2026), 20.83x (Q4 2025), and 15.51x (Q3 2025). The current trailing PE of 19.78x sits in the middle of that historical band — well below the 2021 spike but above the 2022-2023 lows of 8-15x. The PS ratio of 1.56x, however, is near the low end of its historical range (which peaked above 7x in 2025), suggesting that on a sales basis the stock has de-rated significantly. This divergence — mid-range PE but low-end PS — implies the market is pricing in margin normalization and earnings recovery, and that the stock is not obviously expensive on revenue multiples despite its strong price performance.
PE
19.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. The company's net margin has compressed from 10.10% in Q2 2025 to 6.04% in Q1 2026, driven by interest expense rising to $32.1 million from $5.9 million. Negative shareholders' equity, with a debt-to-equity ratio of -4.06, stems from $2.46 billion in buybacks in Q4 2025 alone, leaving little cushion if cash flows decline. Additionally, revenue is highly concentrated in the Nonalcoholic Beverage segment, which accounts for 99.3% of total revenue, making the company vulnerable to shifts in consumer preferences or supply chain disruptions in that single segment.
Market and competitive risks are also present. COKE trades at a trailing PE of 19.78x, which is mid-range historically but above the 8-15x range seen in 2022-2023, and its PEG ratio of 1.87x suggests it is not cheap relative to growth. The stock's beta of 0.547 indicates lower market correlation, but its 6-month relative underperformance of -26.60% versus SPY shows it can lag in certain market environments. Thin analyst coverage (only one analyst) and low daily volume (701,817 shares) increase the risk of sharp price moves on limited news, and the lack of a consensus target means the stock could remain mispriced.
The worst-case scenario would involve a combination of margin deterioration, rising interest rates, and a slowdown in buybacks. If net margin continues to fall and interest expenses remain high, earnings could decline, leading to multiple compression. The 52-week low of $110.60 represents a potential downside of approximately 42.6% from the current price of $192.61. A more realistic bear case might see the stock retest the May 2026 low of $163.43, a decline of about 15.2%. Given the negative equity and lack of analyst support, a severe downturn could push the stock toward the 52-week low, resulting in a loss of over 40% from current levels.
FAQ
The most severe risk is margin compression: net margin fell to 6.04% in Q1 2026 from 10.10% in Q2 2025, driven by interest expense surging to $32.1 million. Second, the company has negative shareholders' equity (debt-to-equity of -4.06) due to massive buybacks, reducing financial flexibility. Third, the stock has thin analyst coverage (only one analyst) and low daily volume (701,817 shares), which can lead to volatile price swings. Fourth, competitive pressures in the nonalcoholic beverage space could erode market share, though the company's 99.3% revenue concentration in this segment makes it particularly vulnerable. These risks are ranked from highest to lowest severity.
The 12-month forecast includes three scenarios: a bull case with 25% probability targeting $219.65-$240, a base case with 55% probability targeting $180-$210, and a bear case with 20% probability targeting $110.60-$163.43. The base case is most likely, assuming revenue grows 3-5% and net margin stabilizes around 6-7%. The bull case requires margin recovery above 8% and continued buybacks, while the bear case involves further margin deterioration and a break below $163 support. The key assumption behind the base case is that interest expenses remain contained and no major operational disruptions occur.
COKE appears fairly valued on earnings and slightly undervalued on sales. The trailing PE of 19.78x is mid-range compared to its historical band of 8-76x, but the PEG ratio of 1.87x indicates it is not cheap relative to growth. The PS ratio of 1.56x is near the low end of its historical range, suggesting the market is pricing in margin normalization. The forward PE of 4.95x is distorted by depressed trailing EPS and should be treated with skepticism. Compared to beverage peers that often trade at 20-25x earnings, COKE is in line. Overall, the market is paying a fair price, with limited margin of safety.
COKE is a Hold-rated stock, not a compelling buy at current levels. The stock trades at a trailing PE of 19.78x and a PEG of 1.87x, suggesting it is fairly valued to slightly rich. While the company generates strong free cash flow of $662.1 million and has reduced share count by 35% in a year, net margin has compressed to 6.04% from 10.10% due to rising interest expenses. The lack of analyst coverage and low liquidity add risk. For income-focused investors, the 0.77% dividend yield and low payout ratio of 15.2% may be attractive, but for growth investors, the 16.88% revenue growth is offset by margin pressures. A better entry point might be near the $163 support level.
COKE is better suited for long-term investment, with a suggested minimum holding period of 2-3 years. The company is a mature, defensive bottler with a beta of 0.547, low volatility, and a consistent dividend, making it appropriate for income and value investors. Short-term trading is less advisable due to low liquidity (701,817 daily volume) and thin analyst coverage, which can cause erratic price movements. The stock's 55% one-year gain was driven by buybacks and multiple expansion, but future returns will likely depend on margin stabilization and continued capital returns. Long-term investors can benefit from the company's cash generation and potential multiple re-rating if margins improve.
